In short
This article discusses a clinical trial investigating the use of Human Albumin As Macroaggregates in combination with other treatments for patients with non-resectable hepatocellular carcinoma (HCC). The study, known as HOLMBRAVE, aims to evaluate the safety and efficacy of selective intra-arterial 166Holmium radiation therapy combined with atezolizumab and bevacizumab for patients with this challenging form of liver cancer.
At a glance
- Study Name
- HOLMBRAVE
- Main Objective
- Evaluate the added value of 166Holmium SIRT to Atezolizumab + Bevacizumab for non-resectable HCC
- Key Inclusion Criteria
- Adults with non-resectable HCC, BCLC stage C, eligible for Atezolizumab and Bevacizumab therapy
- Key Exclusion Criteria
- Complete main portal vein thrombosis, daily oxygen requirement, previous liver radiation therapy
- Primary Endpoint
- Objective response rate at 6 months after 166Holmium SIRT
- Secondary Endpoints
- Response rates, progression-free survival, overall survival, adverse events
- Use of Human Albumin As Macroaggregates
- Part of radiopharmaceutical preparation for imaging purposes
What is Human Albumin as Macroaggregates?
Human Albumin as Macroaggregates is a medical product used in diagnostic imaging procedures. It is a component of a radiopharmaceutical preparation kit called Pulmocis 2 mg. This substance is derived from human albumin, a protein naturally found in blood, which has been processed to form larger particles or aggregates.
How is it used?
Human Albumin as Macroaggregates is primarily used in lung imaging. It is combined with a radioactive substance called Technetium-99m to create a diagnostic tool. When injected into the bloodstream, these macroaggregates temporarily lodge in the small blood vessels of the lungs, allowing for detailed imaging of lung blood flow.
Medical Conditions
While the primary use of this product is for lung imaging, it's important to note that in the clinical trial described, it is being investigated for a different purpose. The trial is exploring its use in patients with non-resectable Hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed.
This highlights an interesting aspect of medical research: sometimes, products originally designed for one purpose (in this case, lung imaging) are investigated for potential benefits in treating other conditions (like liver cancer).
Administration
Human Albumin as Macroaggregates is administered through intravenous injection. This means it is injected directly into a vein, allowing it to circulate quickly throughout the body.
Dosage
The dosage is measured in a unit called MBq (megabecquerel), which is used to measure radioactivity. The maximum daily dose and maximum total dose mentioned in the trial information is 200 MBq. However, it's important to note that the exact dosage would be determined by a healthcare professional based on individual patient factors and the specific purpose of the imaging study.
Safety Considerations
As with any medical procedure involving radiation, there are some safety considerations to keep in mind:
- This product is used under careful medical supervision.
- It's not suitable for everyone. For example, pregnant or breastfeeding women would typically not be given this product.
- Patients with allergies to any components of the product should inform their healthcare provider.
- The radiation exposure is generally considered low and short-lived, but it's always balanced against the medical benefit of the procedure.
It's crucial to remember that while this article provides general information about Human Albumin as Macroaggregates, its use in the mentioned clinical trial for liver cancer is investigational. Always consult with a healthcare professional for medical advice tailored to your specific situation.